LivaNova PLC — Q3 2022 Form 10-Q Summary
Business context and reporting period
LivaNova is a global medical-device company operating through Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS) segments. The filing covers the three and nine months ended September 30, 2022. Financial statements are unaudited, prepared under U.S. GAAP, and reported in U.S. dollars. Prior-year comparative amounts were revised for a foreign-currency inventory and cost-of-sales error.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Revenue | $252.6 million | $253.2 million | $746.9 million | $765.3 million |
| Gross profit | $170.9 million | $168.7 million | $523.7 million | $504.4 million |
| Gross margin | 67.7% | 66.6% | 70.1% | 65.9% |
| Operating income/(loss) | $(132.0) million | $16.4 million | $(90.7) million | $(25.5) million |
| Net income/(loss) | $(107.3) million | $(43.4) million | $(87.9) million | $(130.7) million |
| Diluted loss per share | $(2.01) | $(0.84) | $(1.64) | $(2.63) |
| Operating cash flow | Not separately provided | Not separately provided | $51.2 million | $69.1 million |
Q3 operating margin was approximately negative 52.3%, compared with 6.5% in the prior-year quarter; nine-month operating margin was approximately negative 12.1%, compared with negative 3.3%. Q3 selling, general and administrative expense was $114.6 million, research and development expense was $35.7 million, and interest expense was $12.7 million.
- Cash and cash equivalents were $231.1 million at September 30, 2022, compared with $208.0 million at December 31, 2021.
- Restricted cash was $275.2 million, held as collateral for the SNIA litigation guarantee; total cash, cash equivalents and restricted cash were $506.3 million.
- Total debt obligations were approximately $540.0 million, including $518.2 million of long-term debt and $21.7 million of current debt. The company also had $125.0 million available under its revolving facility and $50.0 million available under the delayed-draw term facility.
- Total assets were $2.21 billion and stockholders’ equity was $1.15 billion at September 30, 2022.
Material changes versus the prior comparable period
- Revenue declined 0.2% in Q3 and 2.4% for the nine-month period, primarily reflecting unfavorable foreign exchange and the absence of Heart Valve revenue following its 2021 divestiture.
- Cardiopulmonary revenue declined 1.8% in Q3 but increased 4.0% for nine months. The nine-month improvement reflected higher oxygenator demand, increased cardiac procedures and heart-lung-machine placements, partly offset by foreign exchange.
- Neuromodulation revenue increased 7.5% in Q3 and 4.6% for nine months, driven by replacement implants and improving market conditions. Segment income increased to $43.3 million in Q3 and $132.1 million for nine months.
- ACS revenue declined 43.9% in Q3 and 28.8% for nine months as ECMO demand fell with fewer severe COVID-19 cases and continued hospital challenges.
- ACS goodwill was fully impaired, resulting in a $129.4 million non-cash impairment charge in Q3 and year to date. The impairment followed a roughly 29% nine-month ACS revenue decline and reduced future revenue projections.
- Q3 other operating expenses increased to $23.1 million, including an $18.6 million increase to the 3T Heater-Cooler litigation provision and $4.1 million of restructuring expense. The nine-month litigation adjustment was $19.3 million, and restructuring expense was $4.6 million.
- Research and development expense declined year over year, partly due to changes in contingent-consideration fair values, although spending increased on the RECOVER, ANTHEM-HFrEF and OSPREY clinical programs.
- Operating cash flow decreased to $51.2 million from $69.1 million, primarily because of higher inventory investment and incentive-plan payments.
- The company acquired the remaining 97% of ALung in May 2022 for consideration valued at approximately $32.4 million at acquisition, with potential additional sales-based payments of up to $100.0 million.
Guidance, outlook, commentary and risks
The filing does not provide clear numerical revenue or earnings guidance. Management stated that, based on its current business plan, cash, operating cash generation and available borrowing capacity are expected to fund operating requirements, capital expenditures, acquisitions and debt service for the twelve months following issuance of the financial statements.
- Management cited continued COVID-19-related procedure volatility, hospital capacity constraints, supply-chain delays, labor shortages, inflation, freight costs and foreign-exchange pressure.
- The strengthened U.S. dollar adversely affected reported revenue and profitability; foreign-exchange movements also materially affected accumulated other comprehensive income.
- The company expects the impact of COVID-19 variants, particularly on Neuromodulation procedures and ACS ECMO demand, to remain uncertain. Clinical studies may also face delays if infections or hospital restrictions recur.
- The company committed to a cost-optimization and workforce-reduction program expected to be completed by mid-2023. Total estimated restructuring costs are approximately $10.0 million.
- The Italian Supreme Court heard the SNIA appeals on October 5, 2022, with a decision expected in the first half of 2023. The Court of Appeal judgment requires approximately €453.6 million of damages, subject to appeal. Payment is suspended while the appeal is reviewed, secured by a €270.0 million bank guarantee and related restricted cash.
- 3T Heater-Cooler product-liability matters remained material. The provision was $46.8 million at September 30, 2022, including a $18.6 million Q3 increase. Approximately 90 filed and unfiled claims were identified as of November 2, 2022, although the ultimate liability may differ from the recorded provision.
- The FDA completed its Munich facility close-out inspection in April 2022 and issued an Establishment Inspection Report in August 2022, but the 2015 Warning Letter had not yet been formally closed.
- Management reported compliance with the financial covenants under the first-lien credit agreement as of September 30, 2022. Variable-rate debt creates exposure to higher interest costs.
- The filing identifies additional risks from the Russia-Ukraine conflict, sanctions compliance, international operations, regulatory approvals, reimbursement, product liability, environmental obligations, cybersecurity and impairment of goodwill or other assets.
Most important facts for investors to verify
- Whether ACS revenue and profitability stabilize after the 2022 ECMO demand decline and $129.4 million goodwill impairment.
- The timing and outcome of the Italian Supreme Court’s SNIA decision and the potential effect on liquidity beyond the restricted collateral already posted.
- Whether 3T Heater-Cooler claims exceed the $46.8 million provision and whether further litigation charges are required.
- Progress toward the cost-reduction program, including workforce actions and total restructuring costs.
- Cash generation, inventory levels and debt-service capacity amid inflation, supply-chain constraints and floating-rate borrowing.
- Formal closure of the FDA Warning Letter and compliance with evolving U.S. and international medical-device regulations.
- The commercial contribution of the ALung acquisition and achievement of its sales-based milestones.